Until recently, genomics was a «read-only» science. But scientists led by Rory Johnson at the University of Bern and the Centre for Genomic Regulation in Barcelona, have now developed a tool for quick and easy deletion of DNA in living cells.
This software will boost efforts to understand the vast regions of non-coding DNA, or «Dark Matter», in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
Genomics is the field of research studying how our «genome», or entire DNA sequence, specifies a human being, and how errors in this sequence give rise to diseases. Genomics was recently a «read-only» endeavour: researchers used powerful technology to read genomes’ sequence and their regulatory layers. However until recently, there was no way to edit or delete DNA for either basic research objectives, or for potential therapeutic interventions.
Just a few years ago, this outlook changed dramatically with the discovery of a revolutionary technique for editing genomes: «CRISPR-Cas9». CRISPR-Cas9 is a molecular tool composed of two simple components: a molecular barcode, called «sgRNA», which is designed by the researcher to recognise one precise location in the genome; and a protein, Cas9, that binds to a structured loop in the sgRNA. By introducing these two units, researchers may perform a wide range of operations on specific pieces of genomic DNA, from introducing small mutations, to regulating gene activity, to tagging it with small sequences. Until recently most studies employing CRISPR-Cas9 were aimed at silencing protein-coding genes, the best-studied part of our genome.
However our genome consists of 99% of DNA that does not encode any protein. Often described as the «Dark Matter» of the genome, this «non-coding DNA» is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution. Until recently, the experimental tools to study this have not been available.
Researchers studying non-coding DNA have been particularly excited about the discovery of CRISPR-Cas9 because it can be used as a powerful tool for studying non-coding DNA for the first time. Prof Rory Johnson, at the Centre for Genomic Regulation (CRG) in Barcelona, Spain and now at the National Center of Competence in Research (NCCR) RNA & Disease and Department of Clinical Research of the University of Bern, recently created a tool based on CRISPR-Cas9, called «DECKO», which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two molecular scissors that snip out a piece of DNA. Numerous researchers worldwide have adopted this approach, attracted by its simplicity and effectiveness.
While working on DECKO, Johnson and colleagues realised that no software was available for designing the pairs of sgRNAs that are required, meaning that designing deletion experiments was time-consuming. To overcome this, Johnson recruited Masters student Carlos Pulido to design a software pipeline called CRISPETa. They were assisted by a team of laboratory researchers including co-first authors of this paper Estel Aparicio and Carme Arnan, who carried out experiments to validate the software’s predictions.
CRISPETa is a powerful and flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind. Importantly, CRISPETa is designed for use by non-experts, and is available in a user friendly website, making CRISPR deletion available to the widest possible number of scientific and biomedical researchers.
In the CRISPETa study, the researchers also introduce a new version of DECKO, which is cheaper and faster than the previous one. The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
CRISPETa will be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state. Therefore CRISPETa will be a valuable tool for the hundreds of research teams worldwide who are using CRISPR deletion.
«We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research», says Carlos Pulido, the student who wrote the CRISPETa software.
«Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations», adds Rory Johnson.
Receive an email update when we add a new GENOMIC MEDICINE article.
The Latest on: Genomic medicine
via Google News
The Latest on: Genomic medicine
- Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaborationon May 12, 2020 at 2:14 am
TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health ...
- Do Jewish genetic diseases increase the risk of COVID-19?on May 12, 2020 at 2:10 am
Blonder has familial dysautonomia (FD), a rare genetic disease with an increased incidence among Jews of Ashkenazi descent. It affects involuntary motion, leading to problems with breath control, ...
- Regeneron and CCPM collaborate to advance human genetics, precision medicineon May 11, 2020 at 4:16 pm
Regeneron Pharmaceuticals, Inc. and the Colorado Center for Personalized Medicine at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to ...
- Genetic variant could identify lung cancer susceptibilityon May 11, 2020 at 8:57 am
An international consortium of researchers have identified a mutation involved in a person’s susceptibility to lung cancer.
- “Direct to Drug” screening as a precision medicine tool in multiple myelomaon May 11, 2020 at 8:54 am
Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug ...
- Regeneron & Colorado Center for Personalized Medicine announce human genetics research collaborationon May 11, 2020 at 6:33 am
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus today announced a large-scale research ...
- Regeneron to collaborate with Colorado U. group in genomic researchon May 11, 2020 at 4:43 am
Regeneron Pharmaceuticals (NASDAQ:REGN) has agreed to collaborate with the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus in a project a ...
- ARK Genomic Revolution Multi-Sector ETF: An Overbought But Promising Niche Playon May 8, 2020 at 7:13 am
I am neutral on ARKG, an exciting, niche biotech ETF that currently looks overbought on the charts. I expect investor interest in this space to stay elevated on ...
- Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcripton May 8, 2020 at 4:40 am
Welcome to Editas Medicine's First Quarter 2020 Conference Call. [Operator Instructions]. I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at ...
via Bing News